A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study

Inclusion Criteria: \- Subjects completing the planned 16 weeks of treatment on the 20010103 Anemia of Cancer protocol Exclusion Criteria: * Subjects currently receiving or planned to receive cytotoxic chemotherapy or myelosuppressive radiotherapy * Subjects who have other diagnoses not related to the cancer which can cause anemia * Known history of seizure disorder * Cardiac condition: uncontrolled angina, congestive heart failure, known ejection fraction less than 40%, or uncontrolled cardiac arrhythmia * Uncontrolled hypertension * Clinically significant systemic infection or chronic inflammatory disease present at the time of enrollment * Subject of reproductive potential who is not using adequate contraceptive precautions * Concerns for subject's compliance with the protocol procedures